Hamed Manoochehri

Hamed Manoochehri

Auto-generated profile, based on publicly available information

Hamed Manoochehri

The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
AAAmirhossein Ahmadieh-Yazdi
Amirhossein Ahmadieh-Yazdi
RVRosario Vicidomini
Rosario Vicidomini
NPNaresh Poondla
Naresh Poondla
HTHamid Tanzadehpanah
Hamid Tanzadehpanah
PDPaola Dama
Paola Dama
In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that have revolutionized the landscape of care for cancer patients. While traditional pillars such as surgery, chemotherapy, and radiation therapy have long been available, a cutting-edge therapeutic approach called CAR T-cell therapy has emerged as a game-changer in treating multiple myeloma (MM). This novel treatment method complements options like autologous stem cell transplants and immunomodulatory medications, such as proteasome inhibitors, by utilizing protein complexes or anti-CD38 antibodies with potent complement-dependent cytotoxic effects. Despite the challenges and obstacles associated with these treatments, the recent approval of the second FDA multiple myeloma CAR T-cell therapy has sparked immense promise in the field. Thus far, the results indicate its potential as a highly effective therapeutic solution. Moreover, ongoing preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for patients with relapsed/refractory MM (RRMM). These advancements have shown the potential for CAR T cell-based medicines or combination therapies to elicit greater treatment responses and minimize side effects. In this context, it is crucial to delve into the history and functions of CAR T-cells while acknowledging their limitations. We can strategize and develop innovative approaches to overcome these barriers by understanding their challenges. This article aims to provide insights into the application of CAR T-cells in treating MM, shedding light on their potential, limitations, and strategies employed to enhance their efficacy.

5 January 2022 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
HMHamed Manoochehri
Hamed Manoochehri
PDPaola Dama
Paola Dama
Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and consolidation chemotherapy alone or in combination with different therapeutic approaches remain the main treatment. Although complete or partial remission of the disease can be achieved, the risk of relapse or refractory leukemia is still high. More effective and safe therapy options are yet unmet needs. In recent years’ new therapeutic approaches have been widely used. Hematopoietic Stem Cell Transplantation (HSCT) presents significant limitations and the outcome of the consolidation treatment is patient dependent. Side effects such as Graft versus Host Disease (GvHD) in allogeneic hematopoietic stem cell transplantation are extremely common, therefore, using alternative methods to address these challenges for treatment seems crucial. In the last decade, T cells genetically engineered with Chimeric Antigen Receptor (CAR) treatment for the ALL are largely studied and represent the new era of strategy. According to the Phase I/II clinical trials, this technology results seem very promising and can be used in the next future as an effective and safe treatment for ALL treatment. In this review different generations, challenges, and clinical studies related to chimeric antigen receptor (CAR) T-cells for ALL treatment are discussed.

14 December 2018 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
PSPouria Samadi
Pouria Samadi
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
HKHamed Manoochehri Khoshinani
Hamed Manoochehri Khoshinani

8 November 2016 in Cancer Investigation
Verified
Journal Article
Closed access
HKHamed Manoochehri Khoshinani
Hamed Manoochehri Khoshinani
SASaeid Afshar
Saeid Afshar
RNrezvan najafi
rezvan najafi
Hypoxia is a common feature of malignant tumors. There is an interactive connection between hypoxia and chemoresistance, radioresistance, invasiveness, and angiogenesis. Therefore, tumor hypoxia has been considered as a validated target for treating cancer. This review focuses on the role of hypoxia on chemoresistance and radioresistance. In addition, we address several approaches targeting tumor hypoxia, known as hypoxia-targeted therapy.

1 May 2020 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
HMHamed Manoochehri
Hamed Manoochehri
NHNashmin Fayazi Hosseini
Nashmin Fayazi Hosseini
MSMassoud Saidijam
Massoud Saidijam
MTMohammad Taheri
Mohammad Taheri
HRHamideh Rezaee
Hamideh Rezaee
FNFatemeh Nouri
Fatemeh Nouri

6 September 2017 in Japanese Journal of Radiology
Verified
Journal Article
Closed access
PDF file
HKHamed Manoochehri Khoshinani
Hamed Manoochehri Khoshinani
SASaeid Afshar
Saeid Afshar
APAbdolazim Sedighi Pashaki
Abdolazim Sedighi Pashaki
AMAli Mahdavinezhad
Ali Mahdavinezhad
SNSafora Nikzad
Safora Nikzad
MSMassoud Saidijam
Massoud Saidijam